Miniatura

Fitxers

651593.pdf (836.2 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-02

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118682

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3324/haematol.2013.087650

Resum

Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available therapy [n=73]) from the two phase 3 COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (COMFORT) studies. Spleen volume was assessed by magnetic resonance imaging/computed tomography at baseline and every 12 weeks through week 72; spleen length was assessed by palpation at each study visit. Health-related quality of life and symptoms were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items at baseline and in weeks 4, 8, 12, 16 and 24 in COMFORT-I and in weeks 8, 16, 24 and 48 in COMFORT-II. The demographic and baseline characteristics were similar between the control arms of the two studies. One patient who received placebo and no patients who received best available therapy had a ≥35% reduction in spleen volume from baseline at week 24. At 24 weeks, neither placebo nor best available therapy had produced clinically meaningful changes in global quality of life or symptom scales. Non-hematologic adverse events were mostly grade 1/2; the most frequently reported adverse events in each group were abdominal pain, fatigue, peripheral edema and diarrhea. These data suggest that non-Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared with placebo. Both COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) studies have been appropriately registered with clinicaltrials.gov.

Matèries

Malalties hematològiques, Placebos, Assaigs clínics de medicaments

Matèries (anglès)

Hematologic diseases, Placebos (Medicine), Drug testing

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

MESA, Ruben a., KILADJIAN, Jean-jacques, VERSTOVSEK, Srdan, AL-ALI, Haifa kathrin, GOTLIB, Jason, GISSLINGER, Heinz, LEVY, Richard, SIULNIK, Andres, GUPTA, Vikas, KHAN, Mahmudul, DIPERSIO, John f., MCQUITTY, Mari, CATALANO, John v., HUNTER, Deborah s., KNOOPS, Laurent, DEININGER, Michael w., CERVANTES REQUENA, F., MILLER, Carole, VANNUCCHI, Alessandro m., SILVER, Richard t., BARBUI, Tiziano, TALPAZ, Moshe, BAROSI, Giovanni, WINTON, Elliott f., MENDESON, Estella, HARVEY, Jimmie h.jr., ARCASOY, Murat o., HEXNER, Elizabeth, LYONS, Roger m., PAQUETTE, Ronald, RAZA, Azra, SUN, William, SANDOR, Victor, KANTARJIAN, Hagop m., HARRISON, Claire n.. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. _Haematologica_. 2014. Vol. 99, núm. 2, pàgs. 292-298. [consulta: 24 de gener de 2026]. ISSN: 0390-6078. [Disponible a: https://hdl.handle.net/2445/118682]

Exportar metadades

JSON - METS

Compartir registre